Table 2.
Treatment characteristics among critically ill patients with bacteremia
| Treatment characteristicsa | N (%), Median (IQR) |
|---|---|
| Empiric antimicrobial treatmentb | |
| Number of unique empiric antimicrobials administered | 2 (2–3) |
| Number of unique adequated empiric antimicrobials administered | 2 (1–2) |
| Overall antimicrobial treatmentsc | |
| Number of unique antimicrobials administered | 3 (3–5) |
| Number of unique adequated antimicrobials administered | 3 (2–3) |
| Top 10 most commonly administered antimicrobials | |
| Piperacillin-tazobactam | 85 (73.9%) |
| Vancomycin | 65 (56.5%) |
| Ceftriaxone | 58 (50.4%) |
| Ciprofloxacin | 42 (36.5%) |
| Meropenem | 35 (30.4%) |
| Metronidazole | 22 (19.1%) |
| Cefazolin | 20 (17.4%) |
| Ampicillin | 19 (16.5%) |
| Tobramycin | 14 (12.2%) |
| Amoxicillin-clavulanate | 11 (9.6%) |
| Underwent a source control procedure | 76 (66.1%) |
aAll data are presented as medians and interquartile ranges (IQR) unless otherwise specified
bEmpiric treatment window defined as period between blood culture collection and finalization
cOverall treatments received within 30 days after blood culture collection
dAdequate antimicrobials defined by in vitro activity against the blood culture pathogen(s)